WallStSmart

Equifax Inc (EFX)vsSBC Medical Group Holdings Incorporated (SBC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Equifax Inc generates 3579% more annual revenue ($6.44B vs $175.17M). SBC leads profitability with a 28.0% profit margin vs 10.7%. EFX appears more attractively valued with a PEG of 1.47. SBC earns a higher WallStSmart Score of 72/100 (B).

EFX

Buy

60

out of 100

Grade: C

Growth: 5.3Profit: 7.0Value: 4.0Quality: 4.5
Piotroski: 5/9Altman Z: 1.89

SBC

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 9.0Value: 6.3Quality: 8.5
Piotroski: 2/9Altman Z: 3.94
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EFXSignificantly Overvalued (-17.4%)

Margin of Safety

-17.4%

Fair Value

$168.28

Current Price

$169.00

$0.72 premium

UndervaluedFair: $168.28Overvalued

Intrinsic value data unavailable for SBC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EFX0 strengths · Avg: 0/10

No standout strengths identified

SBC6 strengths · Avg: 9.7/10
P/E RatioValuation
8.6x10/10

Attractively priced relative to earnings

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

EPS GrowthGrowth
338.9%10/10

Earnings expanding 338.9% YoY

Altman Z-ScoreHealth
3.9410/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
28.0%9/10

Keeps 28 of every $100 in revenue as profit

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Areas to Watch

EFX4 concerns · Avg: 3.8/10
P/E RatioValuation
30.2x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
0.7%4/10

0.7% earnings growth

Altman Z-ScoreHealth
1.894/10

Grey zone — moderate risk

Debt/EquityHealth
1.253/10

Elevated debt levels

SBC3 concerns · Avg: 3.3/10
PEG RatioValuation
1.644/10

Expensive relative to growth rate

Market CapQuality
$423.73M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EFX

Revenue growth of 10.6% demonstrates continued momentum. PEG of 1.47 suggests the stock is reasonably priced for its growth.

Bull Case : SBC

The strongest argument for SBC centers on P/E Ratio, Operating Margin, EPS Growth. Profitability is solid with margins at 28.0% and operating margin at 38.6%. Revenue growth of 13.4% demonstrates continued momentum.

Bear Case : EFX

The primary concerns for EFX are P/E Ratio, EPS Growth, Altman Z-Score.

Bear Case : SBC

The primary concerns for SBC are PEG Ratio, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

EFX profiles as a value stock while SBC is a mature play — different risk/reward profiles.

EFX carries more volatility with a beta of 1.30 — expect wider price swings.

SBC is growing revenue faster at 13.4% — sustainability is the question.

EFX generates stronger free cash flow (205M), providing more financial flexibility.

Bottom Line

SBC scores higher overall (72/100 vs 60/100), backed by strong 28.0% margins and 13.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Equifax Inc

INDUSTRIALS · CONSULTING SERVICES · USA

Equifax Inc. is an American multinational consumer credit reporting agency and is one of the three largest consumer credit reporting agencies, along with Experian and TransUnion. In addition to credit and demographic data and services to business, Equifax sells credit monitoring and fraud prevention services directly to consumers.

SBC Medical Group Holdings Incorporated

INDUSTRIALS · CONSULTING SERVICES · USA

SBC Medical Group Holdings, incorporated in Delaware in 2023 and headquartered in Tokyo, Japan, provides management services to cosmetic treatment centers primarily in Japan, with additional locations in Vietnam and California.

Visit Website →

Want to dig deeper into these stocks?